SCHEMBL6077973

SCHEMBL6077973

COC(=O)C(O)=CC(=O)N(Cc1ccc(C(=O)OC)cc1)OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.44
CYP4A11 Q02928 2/20 0.41
CYP4F2 P78329 1/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
TSHR P16473 2/20 0.40
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
RAB9A P51151 1/20 0.39
CA1 P00915 4/20 0.39
CA2 P00918 4/20 0.39
MAPT P10636 1/20 0.39
CA12 O43570 2/20 0.39
CA9 Q16790 2/20 0.39
CA14 Q9ULX7 2/20 0.39
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6879302 0.91 LOXL2 (0.45) LOXL2CYP4A11CYP4F2ALDH1A1KDM4E
SCHEMBL6879305 0.91 LOXL2 (0.45) LOXL2CYP4A11CYP4F2ALDH1A1KDM4E
SCHEMBL6077162 0.86 KDM4E (0.42) ALDH1A1KDM4ENPC1GAASMN1; SMN2
SCHEMBL6077166 0.86 KDM4E (0.42) ALDH1A1KDM4ENPC1GAASMN1; SMN2
SCHEMBL6076507 0.85 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2TDP1
SCHEMBL6077241 0.85 CA12 (0.42) ALDH1A1KDM4EGAAHPGDRAB9A
SCHEMBL6076512 0.85 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2TDP1
SCHEMBL6077018 0.85 BCL2A1 (0.41) ALDH1A1KDM4ETSHRRAB9A
SCHEMBL6077015 0.85 BCL2A1 (0.41) ALDH1A1KDM4ETSHRRAB9A
SCHEMBL6077249 0.85 CA12 (0.42) ALDH1A1KDM4EGAAHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF LOXL2 4464/4885CYP4A11 269/4885CYP4F2 2008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.